- GSK shares fell ~2% after negative late‑stage trial results for chronic cough drug camlipixant. Citi called the asset high‑risk with ~25% success odds; analysts had modeled 2035 sales ~£750M.
- EMA accepted GSK’s submission to add a one‑dose Bexsero booster for age 10+ for those vaccinated in infancy, seeking label update to allow a single booster from age 10 onward.
TradingView
Key facts: GSK shares fall on camlipixant setback; EMA accepts Bexsero
- Sources
- TradingView
- Markets
- Stocks
- Active symbols
- LSE:GSK
- Language
- English (India)
GSK shares fell ~2% after negative late‑stage trial results for chronic cough drug camlipixant. Citi called the asset high‑risk with ~25% success odds; analysts had modeled 2035 sa